{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:52:34Z","timestamp":1790261554533,"version":"4.1.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","gastrojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1053\/j.gastro.2016.12.049","type":"journal-article","created":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T18:17:45Z","timestamp":1486750665000},"page":"1765-1779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Practical Use of Pharmacotherapy for Obesity"],"prefix":"10.1053","volume":"152","author":[{"given":"Leon I.","family":"Igel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha B.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine H.","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis J.","family":"Aronne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2016.12.049_bib1","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/ijo.2015.59","article-title":"Physiological adaptations to weight loss and factors favouring weight regain","volume":"39","author":"Greenway","year":"2015","journal-title":"Int J Obes (Lond)"},{"key":"10.1053\/j.gastro.2016.12.049_bib2","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.2337\/dc09-1649","article-title":"Testosterone concentrations in diabetic and nondiabetic obese men","volume":"33","author":"Dhindsa","year":"2010","journal-title":"Diabetes Care"},{"issue":"25 Pt B","key":"10.1053\/j.gastro.2016.12.049_bib3","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"63","author":"Jensen","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1053\/j.gastro.2016.12.049_bib4","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an endocrine Society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"Suppl 3","key":"10.1053\/j.gastro.2016.12.049_bib5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologist and American College of Endocrinology Comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1053\/j.gastro.2016.12.049_bib6","first-page":"780","article-title":"Drug-induced weight gain: rethinking our choices","volume":"65","author":"Saunders","year":"2016","journal-title":"J\u00a0Fam Pract"},{"key":"10.1053\/j.gastro.2016.12.049_bib7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4158\/EP151126.CS","article-title":"Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm\u22122016 Executive Summary","volume":"22","author":"Garber","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1053\/j.gastro.2016.12.049_bib8","series-title":"A\u00a0Practical Guide to Drug-Induced Weight Gain","first-page":"77","article-title":"Drug-induced weight gain: non-CNS medications","author":"Aronne","year":"2002"},{"key":"10.1053\/j.gastro.2016.12.049_bib9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/MED.0000000000000095","article-title":"Effects of metformin on weight loss: potential mechanisms","volume":"21","author":"Malin","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1053\/j.gastro.2016.12.049_bib10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11883-016-0568-3","article-title":"Metformin: an old therapy that deserves a new indication for the treatment of obesity","volume":"18","author":"Igel","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"10.1053\/j.gastro.2016.12.049_bib11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrendo.2011.243","article-title":"SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects","volume":"8","author":"Ferrannini","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1053\/j.gastro.2016.12.049_bib12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2337\/diacare.28.1.154","article-title":"Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis","volume":"28","author":"Van de Laar","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2016.12.049_bib13","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/j.1463-1326.2012.01600.x","article-title":"Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study","volume":"14","author":"Hong","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.gastro.2016.12.049_bib14","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2337\/dc09-2191","article-title":"Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study","volume":"33","author":"Arnolds","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2016.12.049_bib15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.diabet.2011.11.001","article-title":"DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials","volume":"38","author":"Scheen","year":"2012","journal-title":"Diabetes Metab"},{"key":"10.1053\/j.gastro.2016.12.049_bib16","doi-asserted-by":"publisher","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2016.12.049_bib17","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1210\/jc.2006-2003","article-title":"Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study","volume":"92","author":"Aronne","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1053\/j.gastro.2016.12.049_bib18","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.amjmed.2006.10.017","article-title":"Body weight changes with beta-blocker use: results from GEMINI","volume":"120","author":"Messerli","year":"2007","journal-title":"Am J Med"},{"key":"10.1053\/j.gastro.2016.12.049_bib19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1046\/j.1467-789X.2001.00044.x","article-title":"Use of beta-blockers in obesity hypertension: potential role of weight gain","volume":"2","author":"Pischon","year":"2001","journal-title":"Obes Rev"},{"key":"10.1053\/j.gastro.2016.12.049_bib20","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1161\/01.HYP.37.2.250","article-title":"Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis","volume":"37","author":"Sharma","year":"2001","journal-title":"Hypertension"},{"key":"10.1053\/j.gastro.2016.12.049_bib21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1751-7176.2009.00119.x","article-title":"Nebivolol in obese and non-obese hypertensive patients","volume":"11","author":"Manrique","year":"2009","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1053\/j.gastro.2016.12.049_bib22","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"283","year":"2000","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2016.12.049_bib23","series-title":"Handbook of Obesity. Volume 2: Clinical Applications, Fourth Edition","first-page":"220","article-title":"Drugs that cause weight gain and clinical alternatives to their use","author":"Bray","year":"2014"},{"key":"10.1053\/j.gastro.2016.12.049_bib24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/oby.20181","article-title":"Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment\u2014a position paper of the The Obesity Society and The American Society of Hypertension","volume":"21","author":"Landsberg","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2016.12.049_bib25","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.4088\/JCP.09r05346blu","article-title":"Antidepressants and body weight: a comprehensive review and meta-analysis","volume":"71","author":"Serretti","year":"2010","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"1","key":"10.1053\/j.gastro.2016.12.049_bib26","first-page":"CD004096","article-title":"Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus","author":"Norris","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.gastro.2016.12.049_bib27","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1210\/jc.2014-3421","article-title":"Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis","volume":"100","author":"Domecq","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1053\/j.gastro.2016.12.049_bib28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.pharmthera.2006.07.002","article-title":"Differentiating antidepressants of the future: efficacy and safety","volume":"113","author":"Rosenzweig-Lipson","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1053\/j.gastro.2016.12.049_bib29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1586\/14737175.7.1.17","article-title":"Bupropion for weight reduction","volume":"7","author":"Gadde","year":"2007","journal-title":"Expert Rev Neurother"},{"issue":"4","key":"10.1053\/j.gastro.2016.12.049_bib30","article-title":"Long-term weight change after initiating second-generation antidepressants","volume":"5","author":"Arterburn","year":"2016","journal-title":"J\u00a0Clin Med"},{"issue":"9896","key":"10.1053\/j.gastro.2016.12.049_bib31","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2016.12.049_bib32","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1176\/ajp.161.10.1837","article-title":"Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder","volume":"161","author":"Simpson","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1053\/j.gastro.2016.12.049_bib33","first-page":"CD006627","article-title":"Ziprasidone versus other atypical antipsychotics for schizophrenia","volume":"4","author":"Komossa","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.gastro.2016.12.049_bib34","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/YIC.0000000000000091","article-title":"Weight change\u00a0during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia","volume":"30","author":"Meyer","year":"2015","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1053\/j.gastro.2016.12.049_bib35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1517\/14740338.2015.974549","article-title":"Weight gain and antipsychotics: a drug safety review","volume":"14","author":"Musil","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1053\/j.gastro.2016.12.049_bib36","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1089\/cap.2011.0015","article-title":"Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents","volume":"21","author":"Maayan","year":"2011","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1053\/j.gastro.2016.12.049_bib37","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3810\/pgm.2012.07.2577","article-title":"Weight gain and\u00a0glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians","volume":"124","author":"Hasnain","year":"2012","journal-title":"Postgrad Med"},{"key":"10.1053\/j.gastro.2016.12.049_bib38","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 7","key":"10.1053\/j.gastro.2016.12.049_bib39","first-page":"22","article-title":"Antipsychotic-induced weight gain: a review of the literature","volume":"62","author":"Allison","year":"2001","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1053\/j.gastro.2016.12.049_bib40","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/oby.2010.176","article-title":"Association of prescription H1 antihistamine use with obesity: results from the National Health and Nutrition Examination Survey","volume":"18","author":"Ratliff","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2016.12.049_bib41","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40263-013-0062-1","article-title":"The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain","volume":"27","author":"He","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1053\/j.gastro.2016.12.049_bib42","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/978-3-642-24716-3_20","article-title":"Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide","volume":"209","author":"Antel","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"10.1053\/j.gastro.2016.12.049_bib43","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1111\/j.1467-789X.2010.00800.x","article-title":"Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications","volume":"12","author":"Verrotti","year":"2011","journal-title":"Obes Rev"},{"key":"10.1053\/j.gastro.2016.12.049_bib44","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/00007691-199708000-00006","article-title":"Changes in body weight with chronic, high-dose gabapentin therapy","volume":"19","author":"DeToledo","year":"1997","journal-title":"Ther Drug Monit"},{"key":"10.1053\/j.gastro.2016.12.049_bib45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1590\/S0004-282X2010000200024","article-title":"Modification in body weight associated with antiepileptic drugs","volume":"68","author":"Gaspari","year":"2010","journal-title":"Arq Neuropsiquiatr"},{"issue":"Suppl 9","key":"10.1053\/j.gastro.2016.12.049_bib46","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1528-1167.2007.01402.x","article-title":"Weight issues for people with epilepsy\u2014a review","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"10.1053\/j.gastro.2016.12.049_bib47","first-page":"CD003987","article-title":"Combination contraceptives: effects on weight","volume":"1","author":"Gallo","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1053\/j.gastro.2016.12.049_bib48","first-page":"CD008815","article-title":"Progestin-only contraceptives: effects on weight","author":"Lopez","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.gastro.2016.12.049_bib49","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.contraception.2012.01.017","article-title":"Body weight and composition in users of levonorgestrel-releasing intrauterine system","volume":"86","author":"Dal'Ava","year":"2012","journal-title":"Contraception"},{"key":"10.1053\/j.gastro.2016.12.049_bib50","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s40265-014-0282-9","article-title":"Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events","volume":"74","author":"Fardet","year":"2014","journal-title":"Drugs"},{"key":"10.1053\/j.gastro.2016.12.049_bib51","series-title":"Clinical Management of Obesity","author":"Apovian","year":"2015"},{"key":"10.1053\/j.gastro.2016.12.049_bib52","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3","article-title":"Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin","volume":"39","author":"Rothman","year":"2001","journal-title":"Synapse"},{"key":"10.1053\/j.gastro.2016.12.049_bib53","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.gtc.2010.01.001","article-title":"Pharmacologic therapies for obesity","volume":"39","author":"Kaplan","year":"2005","journal-title":"Gastroenterol Clin N Am"},{"key":"10.1053\/j.gastro.2016.12.049_bib54","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/oby.20584","article-title":"Evaluation of phentermine and topiramate versus phentermine\/topiramate\u00a0extended-release in obese adults","volume":"21","author":"Aronne","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2016.12.049_bib55","series-title":"Xenical [package insert]","year":"2016"},{"key":"10.1053\/j.gastro.2016.12.049_bib56","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2016.12.049_bib57","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"issue":"9774","key":"10.1053\/j.gastro.2016.12.049_bib58","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2016.12.049_bib59","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"10.1053\/j.gastro.2016.12.049_bib60","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Multicenter, placebo-controlled trial of lorcaserin for weight management","volume":"363","author":"Smith","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2016.12.049_bib61","unstructured":"A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors (CAMELLIA-TIMI). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02019264. Accessed October 2, 2016."},{"issue":"10","key":"10.1053\/j.gastro.2016.12.049_bib62","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1210\/jc.2011-1256","article-title":"A\u00a0one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial","volume":"96","author":"Fidler","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1053\/j.gastro.2016.12.049_bib63","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/oby.2012.66","article-title":"Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOMDM study","volume":"20","author":"O\u2019Neil","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2016.12.049_bib64","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/oby.2008.461","article-title":"Rational design of a combination medication for the treatment of obesity","volume":"17","author":"Greenway","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2016.12.049_bib65","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1244527","article-title":"Update on naltrexone\/bupropion extended-release in the treatment of obesity","author":"Saunders","year":"2016","journal-title":"Expert Opin Pharmacother"},{"issue":"9741","key":"10.1053\/j.gastro.2016.12.049_bib66","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2016.12.049_bib67","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A\u00a0randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2016.12.049_bib68","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2016.12.049_bib69","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.2337\/dc13-0234","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes","volume":"36","author":"Hollander","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2016.12.049_bib70","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2016.12.049_bib71","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"Van Can","year":"2014","journal-title":"Int J Obes (Lond)"},{"key":"10.1053\/j.gastro.2016.12.049_bib72","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A\u00a0randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2016.12.049_bib73","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes Randomized Clinical Trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2016.12.049_bib74","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)"},{"key":"10.1053\/j.gastro.2016.12.049_bib75","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2016.12.049_bib76","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11883-016-0589-y","article-title":"Pharmacologic approaches to weight management: recent gains and shortfalls in combating obesity","volume":"18","author":"Saunders","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"10.1053\/j.gastro.2016.12.049_bib77","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/j.1742-1241.2006.00992.x","article-title":"Prevalence of hypogonadism in males aged at least 45 years: the HIM study","volume":"60","author":"Mulligan","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1053\/j.gastro.2016.12.049_bib78","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.fertnstert.2013.02.039","article-title":"Determinants of testosterone recovery after bariatric surgery: is it only a matter of reduction of body mass index?","volume":"99","author":"Luconi","year":"2013","journal-title":"Fertil Steril"},{"key":"10.1053\/j.gastro.2016.12.049_bib79","first-page":"997","article-title":"Pathogenesis of the decreased androgen levels in obese men","volume":"79","author":"Giagulli","year":"1994","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1053\/j.gastro.2016.12.049_bib80","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1210\/jc.2007-1972","article-title":"Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study","volume":"93","author":"Wu","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1053\/j.gastro.2016.12.049_bib81","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1530\/EJE-07-0663","article-title":"Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism","volume":"158","author":"Loves","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1053\/j.gastro.2016.12.049_bib82","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/obr.12282","article-title":"Testosterone and obesity","volume":"16","author":"Kelly","year":"2015","journal-title":"Obes Rev"},{"key":"10.1053\/j.gastro.2016.12.049_bib83","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2174\/157339912799424573","article-title":"Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review","volume":"8","author":"Saad","year":"2012","journal-title":"Curr Diabetes Rev"},{"key":"10.1053\/j.gastro.2016.12.049_bib84","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1002\/oby.20407","article-title":"Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss","volume":"21","author":"Saad","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2016.12.049_bib85","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/j.orcp.2013.10.005","article-title":"Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study","volume":"8","author":"Haider","year":"2014","journal-title":"Obes Res Clin Pract"},{"key":"10.1053\/j.gastro.2016.12.049_bib86","first-page":"2647","article-title":"Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age","volume":"84","author":"Snyder","year":"1999","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1053\/j.gastro.2016.12.049_bib87","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/MED.0000000000000086","article-title":"Testosterone and weight loss: the evidence","volume":"21","author":"Traish","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1053\/j.gastro.2016.12.049_bib88","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1210\/jc.2009-2354","article-title":"Testosterone therapy in adult men with androgen deficiency syndromes: An Endocrine Society Clinical Practice Guideline","volume":"95","author":"Bhasin","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1053\/j.gastro.2016.12.049_bib89","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1000485","article-title":"Adverse events associated with testosterone administration","volume":"363","author":"Basaria","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2016.12.049_bib90","doi-asserted-by":"publisher","first-page":"e85805","DOI":"10.1371\/journal.pone.0085805","article-title":"Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men","volume":"9","author":"Finkle","year":"2014","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2016.12.049_bib91","doi-asserted-by":"publisher","unstructured":"Vigen R, O\u2019Donnell CI, Baron AE, et\u00a0al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 310:1829\u20131836.","DOI":"10.1001\/jama.2013.280386"},{"key":"10.1053\/j.gastro.2016.12.049_bib92","unstructured":"US Food and Drug Administration Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart\u00a0attack and stroke with use. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm436259.htm. Published March 3, 2015. Accessed November 12, 2016."},{"key":"10.1053\/j.gastro.2016.12.049_bib93","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1001\/jamainternmed.2015.1573","article-title":"Comparative safety of testosterone dosage forms","volume":"175","author":"Layton","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1053\/j.gastro.2016.12.049_bib94","first-page":"3469","article-title":"Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men","volume":"84","author":"Dobs","year":"1999","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1053\/j.gastro.2016.12.049_bib95","unstructured":"Dohle GR, Arver S, Bettocchi C, et\u00a0al. Guidelines on male hypogonadism 2015. Available at: http:\/\/uroweb.org\/wp-content\/uploads\/EAU-Guidelines-Male-Hypogonadism-2015.pdf. Accessed November 12, 2016."},{"key":"10.1053\/j.gastro.2016.12.049_bib96","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.4158\/EP14434.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of testosterone and cardiovascular risk","volume":"21","author":"Goodman","year":"2015","journal-title":"Endocr Pract"},{"key":"10.1053\/j.gastro.2016.12.049_bib97","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.maturitas.2015.11.003","article-title":"EMAS position statement: testosterone replacement therapy in the aging male","volume":"84","author":"Dimopoulou","year":"2016","journal-title":"Maturitas"},{"key":"10.1053\/j.gastro.2016.12.049_bib98","unstructured":"Agency of European Medicine. No consistent evidence of an increased risk of heart problems with testosterone medicines (EMA\/706140). Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2014\/11\/news_detail_002218.jsp&mid=WC0b01ac058004d5c1. Published November 21, 2014. Accessed November 12, 2016."},{"key":"10.1053\/j.gastro.2016.12.049_bib99","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1506119","article-title":"Effects of testosterone treatment in older men","volume":"374","author":"Snyder","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2016.12.049_bib100","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1093\/eurheartj\/ehv346","article-title":"Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men","volume":"36","author":"Sharma","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1053\/j.gastro.2016.12.049_bib101","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.amjcard.2015.11.063","article-title":"Impact of testosterone replacement therapy on myocardial infarction, stroke, and death in men with low testosterone concentrations in an integrated health care system","volume":"117","author":"Anderson","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.gastro.2016.12.049_bib102","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S2213-8587(16)00112-1","article-title":"Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study","volume":"4","author":"Wallis","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.gastro.2016.12.049_bib103","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.chest.2016.05.007","article-title":"Association between testosterone replacement therapy and the incidence of deep vein thrombosis and pulmonary embolism: a retrospective cohort study of the Veterans Administration Database","volume":"150","author":"Sharma","year":"2016","journal-title":"Chest"},{"key":"10.1053\/j.gastro.2016.12.049_bib104","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/CIA.S32036","article-title":"Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS)","volume":"7","author":"Bhattacharya","year":"2012","journal-title":"Clin Interv Aging"},{"key":"10.1053\/j.gastro.2016.12.049_bib105","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3810\/pgm.2013.03.2637","article-title":"12-month observation of testosterone replacement effectiveness in a general population of men","volume":"125","author":"Miner","year":"2013","journal-title":"Postgrad Med"},{"key":"10.1053\/j.gastro.2016.12.049_bib106","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1517\/14740338.2014.950653","article-title":"Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis","volume":"13","author":"Corona","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1053\/j.gastro.2016.12.049_bib107","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/cen.13084","article-title":"Testosterone therapy, association with age, initiation and mode of therapy with cardiovascular events: a systematic review","volume":"85","author":"Albert","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1053\/j.gastro.2016.12.049_bib108","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/ijcp.12319","article-title":"Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study","volume":"68","author":"Traish","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1053\/j.gastro.2016.12.049_bib109","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1439-0272.2008.00880.x","article-title":"Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men","volume":"41","author":"Haider","year":"2009","journal-title":"Andrologia"},{"key":"10.1053\/j.gastro.2016.12.049_bib110","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/ijcp.12876","article-title":"Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME)","volume":"70","author":"Maggi","year":"2016","journal-title":"Int J Clin Pract"},{"key":"10.1053\/j.gastro.2016.12.049_bib111","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1002\/oby.21533","article-title":"Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s","volume":"24","author":"Thomas","year":"2016","journal-title":"Obesity (Silver Spring)"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508517301427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508517301427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T11:24:07Z","timestamp":1536060247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508517301427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":111,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0016508517301427"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2016.12.049","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical Use of Pharmacotherapy for Obesity","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2016.12.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the AGA Institute","name":"copyright","label":"Copyright"}]}}